Detecting Dilated Cardiomyopathy Using AI-Enhanced Mobile ECG Screening for First-Degree Relatives of Affected Patients

What this Trial Is About

Researchers are evaluating the use of an Artificial Intelligence AI enhanced 6-lead mobile electrocardiogram EKG to encourage first-degree relatives of people with dilated cardiomyopathy DCM to get proper heart screening. This study focuses on relatives of patients with DCM, a heart condition involving reduced left ventricular function, by using a handheld device that records EKGs quickly and transmits the data for AI analysis. Participants include probands with DCM and their first-degree relatives. The study uses the AliveCor KardiaMobile 6L device, which connects wirelessly to a smartphone or tablet to capture heart signals. The AI analyzes these signals to predict reduced heart function. Probands clinical 12-lead EKGs, if available within 30 days, will be compared to the AI results. Relatives are encouraged to follow heart screening guidelines recommended by heart associations. During the study, participants will complete mobile EKG tests, and results will be shared electronically or verbally. Researchers will collect data on how many relatives undergo heart screening after the AI test, monitor positive AI-EKG results, and gather echocardiogram results up to six months after enrollment. The primary goal is to assess how feasible this AI screening approach is and its impact on relatives obtaining cardiac evaluations.

Dilated Cardiomyopathy Detection Using AI and Screening With Mobile Technology (DCM-DETECT)